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Abstract In contrast to the preponderance of affected males in
families with X-linked mental retardation, Rett syndrome (RTT)
is a neurological disorder occurring almost exclusively in
females. The near complete absence of affected males in RTT
families has been explained by the lethal effect of an X-linked
gene mutation in hemizygous affected males. We report here on a
novel mutation (A140V) in the MECP2 gene detected in one
female with mild mental retardation. In a family study, the
A140V mutation was found to segregate in the affected daughter
and in four adult sons with severe mental retardation. These
results indicate that MECP2 mutations are not necessarily lethal
in males and that they can be causative of non-specific X-linked
mental retardation. ß 2000 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
Key words: X-linked mental retardation; MECP2 gene;
Missense mutation; Development
1. Introduction
X-linked mental retardation is a common clinical condition
that can be caused by defects in any of a number of genes [1^
7]. Among the well characterized X-linked conditions causing
mental retardation, mutations in the methyl-CpG binding
protein 2 (MECP2) gene on Xq28 have been found in patients
with Rett syndrome (RTT), a neurological condition [8,9]
which, in addition to other symptoms, severely a¡ects higher
cognitive functions in females. A wide degree of phenotypic
variability has been observed in patients with MECP2 gene
mutations [10^13], and it has been explained either by skewed
X chromosome inactivation (XCI) or by the type and the
relative position of the mutation observed. The phenotypic
variability in these patients ranges from display of all symp-
toms of RTT to essentially only mild mental retardation [10^
13]. To further investigate the occurrence of MECP2 muta-
tions in mental retardation, we performed a mutation analysis
of the MECP2 gene in 76 female patients with various types
of mental retardation. Novel and known mutations in the
MECP2 gene were found in patients with classical and variant
RTT and in a patient who presented with full classical autism
and some of the signs of RTT. In addition, a novel mutation
(A140V) in the MECP2 gene was detected in one female with
mild mental retardation. The A140V mutation was found to
segregate in the a¡ected daughter and in four adult sons with
severe mental retardation. These ¢ndings indicate that
MECP2 mutations are not necessarily lethal in males and
can be causative of non-speci¢c X-linked mental retardation.
2. Materials and methods
Genomic DNA from leukocytes of peripheral venous EDTA blood
or from lymphoblastoid cell lines was extracted by standard proce-
dures [14]. The androgen receptor polymorphism was always analyzed
in DNA from peripheral blood leukocytes. All the exons and the
£anking regions of the MECP2 gene were ampli¢ed by PCR as de-
scribed [10]. Heteroduplex analysis was performed on a WAVE1
denaturing high-performance liquid chromatography (DHPLC) in-
strument (Transgenomic). The WAVE utility software was used to
determine the correct temperature for mutation scanning based on
the sequence of the wild-type DNA. Direct sequencing of the PCR
products was performed using the automated £uorescence-based di-
deoxynucleotide termination method (model 310 ABI, PE Biosystems,
Foster City, CA, USA). Both strands were sequenced to con¢rm all
the mutations detected. Sequencing results were compared with the
reference human MECP2 sequence (GenBank accession number
X99686).
3. Results
In order to further analyze the role of MECP2 gene muta-
tion in RTT and general mental retardation, 76 unrelated
females with mental retardation were screened for mutations
in this gene. Towards this aim, all the exons and the £anking
regions of the MECP2 gene were ampli¢ed by PCR and an-
alyzed for heteroduplex formation by DHPLC and by direct
DNA sequencing. In the course of the study, three silent poly-
morphic variants were found. These include a previously re-
ported [10] silent conservative polymorphism (656CCT)
found in two unrelated patients (X119 and X226), and two
novel polymorphisms, (1145CCT), changing codon 357 from
AGC to AGT, both encoding serine, found in patient X388,
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and a IVS2 361CCG, which does not alter the site of splic-
ing, found in patient X231.
Mutations in the MECP2 gene were found in three of the
¢ve patients with clinical features that ful¢lled the criteria for
RTT [15^16]. In patient CL90, a 502CCT mutation was
found that results in R168X. In patients CL82 and CL91 a
763CCT mutation resulting in R255X was observed (Table
1). Both mutations have been previously reported [11]. The
R255X mutation was also identi¢ed in one patient (C4) out of
four who were clinically assessed as RTT variants, as they did
not show the full clinical spectrum of RTT symptoms [17^19].
Patient C4 is an 11-year-old girl. The ¢rst 20^24 months of
her psychomotor development were reported to be normal.
After the age of 2, she became less reactive and began to
show stereotyped hand movements and teeth grinding (brux-
ism). Currently, she presents with severe mental retardation
and speech impairment and displays an unusually aggressive
character. She is able to ambulate independently and to run
and can use her hands adequately for her mental age. There is
no evidence of kyphoscoliosis, microcephaly, hyperventilation,
or seizures. As a whole, the clinical features had suggested
that this case was an atypical and milder RTT variant. The
XCI pattern of patient C4 was evaluated, as females with
completely skewed XCI present a closer to normal phenotype
[10^13,20,21]. Androgen receptor polymorphism detection
[20,21] of patient C4 revealed a skewed ratio of androgen
receptor alleles of more than 80% (data not shown).
A novel MECP2 missense mutation was detected in one of
42 patients with autistic disorder diagnosis. The a¡ected pa-
tient, X44, is a severely retarded girl who presents a full au-
tistic picture with impairment of speech and communication.
She is a 12-year-old girl, adopted at 2 years of age from a
Romanian institute and little is known about her early devel-
opment. At 5 years she had an EEG with bou¡ees of theta
waves which could be compatible with a third stage of RTT
syndrome EEG. Now she presents a full autistic picture,
shows ‘squeezing’ stereotypic activities of her hands, which
are frequently clapped together, and bruxism. She has signi¢-
cant di⁄culties in social interaction and communication,
although in recent years she has learned to pronounce a few
words. She walks without assistance and has good use of her
hands; there is no evidence of seizures, kyphoscoliosis and
microcephaly. The diagnosis of autism was based on clinical
features and evaluated by diagnostic criteria from the Autism
Behavior Checklist and DSM-IV [22,23]. Following a more
recent clinical evaluation, the girl was also found to display
¢ve of the diagnostic criteria for RTT syndrome, which would
also qualify her as a RTT variant, in addition to autistic
features. The mutation (682CCT) found in this patient re-
sults in the substitution T203M. The amino acid residue at
position 203 is not conserved among di¡erent species. In hu-
man it is T, in mouse A, in chicken G, and in Xenopus laevis
K [24,25]. Nevertheless, the 682CCT mutation was not ob-
served in 200 normal X chromosomes, and, as it occurs near
the transcription repression domain start site (codons 207^
Fig. 1. Electrophoretograms showing 493CCT found in the family
of patient X309: (a) X309 (a¡ected heterozygote); (b) X307 (af-
fected hemizygote); (c) MR47 (normal hemizygote); (d) pedigree of
the family of patient X309.
Table 1
MECP2 mutations and genotype^phenotype relationships
Patient Nucleotide
change
Amino acid
change
Phenotype
CL90 C502T R168X RTT
CL82 C763T R255X RTT
CL91 C763T R255X RTT
C4 C763T R255X RTT variant
X44 C682T T203M Autistic/RTT variant
X309 C493T A140V Mild non-speci¢c MR
MR49 C493T A140V Mild non-speci¢c MR
X307 C493T A140V Severe non-speci¢c MR
MR48 C493T A140V Severe non-speci¢c MR
MR50 C493T A140V Severe non-speci¢c MR
X308 C493T A140V Severe non-speci¢c MR
MR47 ^ ^ Normal
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310), it may result in a protein with altered function [10^13].
The XCI pattern of this patient was found to be close to
random (data not shown).
In a third group of 25 females considered to be mildly
mentally retarded, a novel missense mutation in MECP2
was found in patient X309 (Fig. 1). This patient is a 63-
year-old mildly retarded female with microcephaly, asternic
habitus with poorly muscled build, speech di⁄culties, genu
valgum and gait disturbance. The mutation (493CCT) results
in an A140V substitution. The alanine in position 140 is lo-
cated in the methyl-CpG binding domain (MBD) and is
strictly conserved from mammals to Xenopus laevis [10].
Five missense mutations causing classical RTT have been al-
ready identi¢ed in the MBD (R106W, R133C, F155S, F155I
and T158M), but mutations of residue 140 have not been
found in any of the patients with classical RTT and RTT
variant (approx. 250) previously described [10^13,26]. The
MBD of MeCP2 can recognize a single symmetrically meth-
ylated CpG in the major groove of DNA. This domain con-
sists of a wedge-shaped structure with an K-helix constituting
one face of the wedge and with four antiparallel L-strands
constituting the other face of the wedge (Protein Data Bank
ID 1QK9 [27]). Interestingly, A140 is located in the middle of
the K-helix. Using several programs for secondary structure
prediction (http://pbil.ibcp.fr), the substitution of a valine for
alanine at position 140 appears to shorten the K-helix length
by half. We therefore propose that A140V has a subtle e¡ect
on MeCP2 function by altering the wedge-shaped structure of
the MBD.
Investigation of the family of patient X309 revealed that she
had ¢ve living children. Of these, four sons presented with
severe mental retardation and movement disorders. The single
daughter is a 41-year-old woman, who presented with a mild
mental handicap with clinical features similar to those of her
mother. The four a¡ected sons, aged 27^40 years, have a
normal head size, severe mental retardation with friendly per-
sonalities, impaired expressive language development, resting
tremors, and slowness of movements. These subjects did not
show a history of regression of higher brain functions after an
initial normal development. In particular, there was no dete-
rioration in language skills, which always appeared very poor.
A¡ected males put only some words together and communi-
cate in short and simple sentences, and the relatively better
speech of a¡ected females appears related only to simpler
aspects of their everyday life. None of the a¡ected members
had autistic-like behaviors. An apparently una¡ected son died
accidentally when he was 4 years old. Following detection of
the A140V mutation in the mother, the family was clinically
re-evaluated and the MECP2 genotype determined in all
available family members. All the a¡ected sons (X307,
MR48, MR50 and X308) and the daughter (MR49) were
found to carry the A140V mutation. The mutation was not
detected in the normal father (MR47) nor in 300 X chromo-
somes from normal individuals. XCI patterns of patient X309
and her daughter (MR49) were analyzed at the androgen re-
ceptor locus and revealed a close to random pattern of inac-
tivation (data not shown).
4. Discussion
The ¢nding of a MECP2 mutation in a patient with a
diagnosis of autism, together with similar ¢ndings reported
elsewhere [11,28], suggests that females with unexplained men-
tal retardation, especially individuals with autistic-like behav-
ior, should be screened for mutations in the MECP2 gene. As
suggested by Cheadle et al. [13], missense mutations, like
A140V, could correlate with milder diseases than those sus-
tained by truncating mutations, possibly through the presence
of a residual protein function. Previous to this report, RTT
alleles were thought to be lethal for males [29]. The lack of
surviving a¡ected males in the few known RTT families and
the absence of spontaneous cases of a¡ected males with clas-
sical RTT supported this contention [10,11,29]. Further evi-
dence that non-functional MECP2 alleles were lethal for
males has also been provided by experimental work with em-
bryonic stem (ES) cells carrying the null MECP2 allele. Dele-
tion of the MECP2 gene in male murine ES cells a¡ects the
ability of these cells to progress through development, indicat-
ing that a functional MECP2 gene is essential for cell develop-
ment and di¡erentiation during embryogenesis [30]. In this
context, the analysis of the family of patient X309, where a
mutation in MECP2 is observed in mentally retarded adult
males, inherited from the a¡ected mother, indicates for the
¢rst time that not all mutations in MECP2 are necessarily
lethal in males and indicates that the MECP2 gene is a po-
tential candidate in non-speci¢c X-linked mental retardation
in both female and male patients.
Clinical evaluation of these patients agrees with the A140V
being a mild mutation, as the female patients, who have a
random XCI pattern (at least in peripheral blood leukocytes),
only present with a mild form of mental retardation, while the
more severe form of mental retardation in the sons is likely
due to their hemizygous condition. Therefore, the A140V mu-
tation in males appears to allow the execution of the devel-
opmental program involved in birth and survival of male in-
dividuals, yet it can still cause a severe form of mental
retardation in these patients.
Thus the MECP2 gene is a potential candidate in non-spe-
ci¢c X-linked mental retardation (MRX) in both female and
male patients, and a likely candidate for those MRX families
(MRX3, MRX16, MRX25 and MRX28) previously mapped
to loci on Xq28 [3,31]. Our ¢ndings support that the pheno-
typic spectrum due to MECP2 mutations can extend beyond
the traditional RTT diagnostic boundaries. As more becomes
known about the interacting and/or target proteins associated
with MeCP2, we envisage that molecular analysis of the di¡er-
ent MECP2 alleles and especially of the A140V mutation
could provide insight into the roles and epigenetic mecha-
nisms of the MECP2 gene product in various developmental
programs.
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